A Hypothesis of Thyroid-Catecholamine-Receptor Interaction: Its Relevance to Affective Illness

Archives of General Psychiatry

Volumn 38, Issue 1, 1981, Pages 106-113

  Whybrow, Peter C ^a   Prange, Arthur J ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM CARBONATE; NORADRENALIN; PHENYLEPHRINE; PROPRANOLOL; PROTIRELIN; SALBUTAMOL; THYROID HORMONE; THYROTROPIN; THYROXINE; TYRAMINE; TYROSINE;

AFFECTIVE NEUROSIS; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; DEPRESSION;

ADENOSINE MONOPHOSPHATE; BIPOLAR DISORDER; CATECHOLAMINES; DEPRESSIVE DISORDER; HUMAN; LITHIUM; MOOD DISORDERS; NOREPINEPHRINE; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, BETA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THYROID HORMONES; THYROTROPIN; TRIIODOTHYRONINE;

EID: 0019506413     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1981.01780260108012     Document Type: Article

References (118)

1. Rush B: An inquiry into the functions of the spleen, liver, pancreas, and thyroid gland. Med Physic J London 1806;16: 193–208.
2. Harrington CR: Biochemical basis of thyroid function. Lancet 1935;1: 119–204.
3. Prange AJ, Wilson JC, Wabon AM, et al: Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969;126: 457–469.
4. Coppen A, Whybrow PC, Noguera R, et al: The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26: 234–241.
5. Feighner JP, King LJ, Schuckit MA, et al: Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972;128: 1230–1238.
6. Prange AJ Jr, in discussion, Feighner JP, King LJ, Schuckit MA, et al: Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972; 128: 1230–1238.
7. Wheatley D: Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972;26: 229–233.
8. Prange AJ, Wilson IC, Knox A, et al: Enhancement of imipramine by thyroid stimulating hormone: Clinical and theoretical implications. Am J Psychiatry 1970;127: 191–199.
9. Ogura C, Okuma T, Uchida Y, et al: Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974;28: 179–186.
10. Earle BV: Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry 1970;126: 1667–1669.
11. Karlberg BE, Kjellman BF, Kagedal B: Treatment of endogenous depression with oral thyrotropin releasing hormone and amitriptyline. Acta Psychiatr Scand 1978;58: 389–400.
12. Whybrow PC, Coppen A, Prange AJ Jr, et al: Thyroid function and the response to liothyronine in depression. Arch Gen Psychiatry 1972;26: 242–245.
13. Dewhurst DE, El Kabir DJ, Harris GW, et al: Observations on the blood concentration of thyrotrophic hormone (TSH) in schizophrenia and the affective states. Br J Psychiatry 1969;115: 1003–1011.
14. Kirkegaard C, Norlem N, Lauridsen UB, et al: Protirelin stimulation test and thyroid function during treatment of depression. Arch Gen Psychiatry 1975;32: 1115–1118.
15. Gregoire F, Brauman H, deBuck R, et al: Hormone release in depressed patients before and after recovery. Psychoneuroendocrinology 1977;2: 303–312.
16. Josephson AM, MacKenzie TB: Appearance of manic psychosis following rapid normalization of hypothyroidism. Am J Psychiatry 1979;136: 846–847.
17. Cooper TB, Simpson GM: Lithium and the thyroid: Current findings in man, in Prange AJ (ed): The Thyroid Axis, Drugs, and Behavior. New York, Raven Press, 1974.
18. Kunos G, Vermes-Kunos I, Nickerson M: Effects of thyroid state on adrenoreceptor properties. Nature 1974;250: 779–781.
19. Fregly MF, Nelson EL, Resch GE, et al: Reduced beta adrenergic responsiveness in hypothyroid rats. Am J Physiol 1975;229: 916–924.
20. Rosenqvist U: Inhibition of noradrenaline-induced lipolysis in hypothyroid subjects by increased alpha adrenergic responsiveness. Acta Med Scand 1972;192: 353–359.
21. Gjessing RR: Disturbances of somatic functions in catatonia with a periodic course, and their compensation. J Med Sci 1938;84: 608–621.
22. Wakoh T, Hatotani N: Endocrinological treatment of psychoses, in Lissak K (ed): Hormones and Brain Function. New York, Plenum Press Inc, 1971.
23. Hatotani N: Endocrinological studies on periodic psychoses, in Lissak K (ed): Hormones and Brain Function. New York, Plenum Press Inc, 1971.
24. Board F, Persky H, Hamburg DA: Psychological stress and endocrine function. Psychom Med 1956;18: 324–336.
25. Burger A, Suter P, Nicod P, et al: Reduced active thyroid hormone levels in acute illness. Lancet 1976;1: 653–655.
26. Chopra IJ, Solomon DH, Hepner GW, et al: Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med 1979;90: 905–912.
27. Cohen KL, Swigar ME: Thyroid function screening in psychiatric patients. JAMA 1979;242: 254–257.
28. Swain CT, Hershman JM: Clinical use of thyrotropin-releasing hormone. Pharmacol Ther C 1976;1: 351–366.
29. Prange AJ, Loosen PT, Neuroff CB: Peptides: Application to research in nervous and mental disorders, in Fielding S (ed): New Frontier of Psychotropic Drug Research. New York, Futura Publishing Co, 1979.
30. Ingbar SH, Woeker KA: The thyroid gland, in William RH (ed): Textbook of Endocrinology. Philadelphia, WB Saunders Co, 1974.
31. Takahashi S, Kondo H, Yoshimura M, et al: Thyrotropin responses in TRH in depressive illness relating to clinical subtypes and the prolonged duration of depressive episode. Folia Psychiatr Neurol Jpn 1974;28: 335–365.
32. Carroll BJ: Neuroendocrine function in psychiatric disorders, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978.
33. Loosen PT, Prange AJ: The TSH response to TRH: Findings in depressed women and depressed alcoholic men, in Goodwin D (ed): Alcoholism and Affective Disorders. Jamaica, NY, Spectrum Publications, 1979.
34. Goshing PH: Thyroid and adrenocortical function in psychiatric illness. Lancet 1968;2: 1343–1346.
35. Feldmesser-Reiss EE: The application of triiodothyronine on the treatment of mental disorders. J Nerv Ment Dis 1958;127: 540–548.
36. Flach FF, Celian CI, Rawson RW: Treatment of psychiatric disorders with tri-iodothyronine. Am J Psychiatry 1958;114: 841–845.
37. Garbutt J, Malekpour B, Brunswick D, et al: Effects of L-triiodothyronine on drug levels and cardiac function in imipramine-treated depressed patients. Am J Psychiatry 1979;136: 980–982.
38. Goodwin FK, Ebert MH: Recent advances in drug treatment of affective disorders, in Jarvik ME (ed): Psychopharmacology in the Practice of Medicine. New York, Appleton-Century-Crofts, 1977.
39. Prange AJ, Wilson IC, Breese GR, et al: Hormonal alteration of imipramine response: A review, in Sachar EJ (ed): Hormones, Behavior, and Psychopathology. New York, Raven Press, 1976.
40. Whybrow PC: Synergistic action between iodine and lithium. JAMA 1972;221:506.
41. Schou MA, Amdisen S, Jensen E, et al: Occurrence of goitre during lithium treatment. Br Med J 1968;3: 710–713.
42. Rogers M, Whybrow PC: Clinical hypothyroidism occurring during lithium treatment: Two case histories and a review of thyroid function in 19 patients. Am J Psychiatry 1971;128: 158–162.
43. Lazarus JH, Richards AR, Addison GM: Treatment of thyrotoxicosis with lithium carbonate. Lancet 1974;2: 1160–1163.
44. Temple R, Berman M. Robbins J, et al: The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972;51: 2746–2756.
45. Etkin W: The thyroid: A gland in search of a function. Perspect Biol Med 1978;22(Autumn): 19–30.
46. Dratman MB: The mechanism of thyroxine action, in Li CH (ed): Hormonal Proteins and Peptides. Volume 6: Thyroid Hormones, New York, Academic Press Inc, 1978.
47. Saavedra JM, Torda T: Increased brain stem and decreased hypothalamine adrenaline-forming enzyme after acute and repeated immobilization stress in the rat. Neuroendocrinology 1980;31: 142–146.
48. Bloom FE: The fine structural localization of biogenic monoamines in nervous tissue. Int Rev Neurobiol 1970;13: 27–36.
49. Chase TN: Catecholamine metabolism and neurologic disease, in Usdin E, Snyder S (eds): Frontiers in Catecholamine Research. New York, Pergamon Press, 1973.
50. Snyder SH, Banerjee SP: Amines in schizophrenia, in Usdin E, Snyder S (eds): Frontiers in Catecholamine Research. New York, Pergamon Press, 1973.
51. Prange AJ: The pharmacology and biochemistry of depression. Dis Nerv Syst 1964;25: 217–221.
52. Schildkraut JJ: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965;122: 509–522.
53. Shopsin B, Friedman E, Gershon S: Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33: 811–819.
54. Whybrow PC, Parlatore A: Melancholia, a model in madness: A discussion of recent psychobiologic research into depressive illness. Psychiatr Med 1973;4: 351–378.
55. Prange AJ Jr, Wilson IC, Lynn CW, et al: L-Tryptophan in mania: Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974;30: 56–62.
56. Innes IR, Nickerson M: Norepinephrine, epinephrine and the sympathomimetic amines, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan Publishing Co Inc, 1975.
57. Smals AGN, Ross HA, Kloppenborg PWC: Seasonal variation in serum T3 and T4 levels in man. J Clin Endocrinol Metab 1977;44: 998–1001.
58. Konno N: Comparison between the thyrotropin response to thyrotropin-releasing hormone in summer and that in winter in normal subjects. Endocrinol Jpn 1978;25: 635–639.
59. Beck U, Reinhardt H, Kendel K, et al: Temperature and endocrine activity during sleep in man. Arch Psychiatr Nervenkr 1976;222: 245–256.
60. Mason JW: A review of psychoendocrine research on the pituitarythyroid system. Psychosom Med 1968;30: 666–681.
61. Mason JW, Jougey EN, Brady JV, et al: Thyroid (plasma butanolextractable iodine) responses to 72-hour avoidance sessions in the monkey. Psychosom Med 1968;30: 682–695.
62. Stumpf WE, Sar M: Localization of thyroid hormones in the mature rat brain and pituitary, in Stumpf WE, Grant LD (eds): Anatomical Neuroendocrinology. New York, S Karger AG, 1975.
63. Villani S, Weitzel WD: Secondary mania. Arch Gen Psychiatry 1979;36:1031.
64. Whybrow PC, Prange AJ Jr, Treadway CR: Mental changes accompanying thyroid gland disfunction: A reappraisal using objective psychological measurement. Arch Gen Psychiatry 1969;20: 48–63.
65. Whiting EG: Thyroid delirial states. Southwest Med 1968;10: 179–181.
66. Goetsch E: New methods in the diagnosis of thyroid disorders: Pathological and clinical. NY State J Med 1918;18: 257–267.
67. Harrison TS: Adrenal, medullary, and thyroid relationships. Physiol Rev 1964;44: 161–185.
68. Breese G, Prange AJ, Lipton MA: Pharmacological studies of thyroidimipramine interactions in animals, in Prange AJ (ed): The Thyroid Axis, Drugs, and Behavior. New York, Raven Press, 1974.
69. Askew BM: Hyperpyrexia as a contributing factor in the toxicity of amphetamine to aggregated mice. Br J Pharmacol 1962;19: 245–257.
70. Coville PF, Telford JM: The effect of thyroid hormones on the action of some centrally acting drugs. Br J Pharmacol 1970;40: 747–758.
71. Lipton MA, Prange AJ, Dairman W, et al: Increased rate of norepinephrine biosynthesis in hypothyroid rats. Fed Proc 1968;27: 399–400.
72. Prange AJ, Meek JL, Lipton MA: Catecholamines: Diminished rate of synthesis in rat brain and heart after thyroxine pretreatment. Life Sci 1970;9: 901–907.
73. Stolk JM, Whybrow PC: Clinical and experimental interrelationships between sympathetic nervous system activity and pituitary-thyroid function, in Proceedings of the Akademiai Kiado: Symposium of the International Society of Psychoneuroendocrinology. Budapest, Hungarian Academy of Sciences, 1976, pp 273–290.
74. Von Euler US: Regulation of catecholamine metabolism in the sympathetic nervous system. Pharmacol Rev 1972;24: 365–369.
75. Prange AJ, Wilson J, Know A, et al: Thyroid-imipramine clinical and chemical interaction evidence for receptor deficit in depression. J Psychiatr Res 1972; 9: 187–205.
76. Sutherland EW, Oye I, Butcher RW: The action of epinephrine and the role of adenyl cyclase system in hormone action. Recent Prog Horm Res 1965;21: 623–646.
77. Pollet RJ, Levey GS: Principles of membrane receptor physiology and their application to clinical medicine. Ann Intern Med 1980;92: 663–680.
78. Ahlquist RP: A study of the adrenotropic receptors. Am J Physiol 1948;153: 586–600.
79. Koelle GB: Neurohumoral transmission and the autonomic nervous system, in Goodman LS, Gilman A (eds): Pharmacological Basis of Therapeutics. New York, Macmillan Publishing Co Inc, 1975.
80. Sulser F, Vetulani J: The noradrenergic cyclic AMP generating system in the limbic forebrain: A functional post-synaptic norepinephrine receptor system and its modification by drugs which either precipitate or alleviate depression, in Hamin I, Usdin E (eds): Animal Models in Psychiatry and Neurology. New York, Pergamon Press, 1977.
81. MacLean PD: The triune brain, emotion, and scientific bias, in Schmitt FO (ed): The Neurosciences. New York, The Rockefeller University Press, 1970.
82. Cannon WB, Rosenblueth A: The Super-Sensitivity of Denervated Structures: A Law of Denervation: New York, Macmillan Publishing Co Inc, 1949.
83. Heydorn W, Frazer A, Mendels J: Do tricyclic antidepressants enhance adrenergic transmission? An update. Am J Psychiatry 1980;137: 113–114.
84. Trendelenburg U: Supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol Rev 1963;15: 225–276.
85. Ashcroft GA, Eccleston D, Murray LG, et al: Modified amine hypothesis for the etiology of affective illness. Lancet 1972;2: 573–577.
86. Mandell AJ: Neurobiological mechanisms of presynaptic metabolic adaptation and their organization: Implications for a pathophysiology of the affective disorders, in Mandell AJ (ed): Neurobiological Mechanisms of Adaptation and Behavior. New York, Raven Press, 1975.
87. Bunney WE, Post RM, Andersen AE, et al: A neuronal receptor sensitivity mechanism in affective illness [A review of evidence]. Commun Psychopharmacol 1977;1 [4]: 393–405.
88. Prange AJ, McCurdy RL, Cochrane CM: The systolic blood pressure response of depressed patients to infused norepinephrine. J Psychiatr Res 1967;5: 1–13.
89. Friedman MJ: Does receptor supersensitivity accompany depressive illness? Am J Psychiatry 1978;135: 107–109.
90. Pickar D, Cohen RM, Murphy DL, et al: Tyramine infusions in bipolar illness: Longitudinal changes in pressor sensitivity and behavior effects. Am J Psychiatry 1979;136: 1460–1463.
91. Ghose K, Turner P, Coppen A: Intravenous tyramine response in depression. Lancet 1975;1: 1317–1318.
92. Coppen A, Ghose K: Peripheral and adrenoreceptor and central dopamine activity in depressed patients. Psychopharmacology 1978;59: 171–177.
93. Murphy DL, Donnelly C, Moskowitz J: Catecholamine receptor function in depressed patients. Am J Psychiatry 1974;131: 1389–1391.
94. Wang YC, Pangy GN, Mendels J, et al: Platelet adenylate cyclase responses in depression: Implications for a receptor defect. Psychopharmacologia 1974;36: 291–300.
95. Pandy GN, Dysken MW, Garver DL, et al: Beta adrenergic function in affective illness. Am J Psychiatry 1979;136: 675–678.
96. Graettinger JS, Muenster JJ: A correlation of clinical and haemodynamic studies in patients with hyperthyroidism with and without congestive failure. J Clin Invest 1959;38: 1316–1327.
97. Grossman W, Rubin NJ, Johnson LW, et al: Effects of beta blockade on the peripheral manifestations of thyrotoxicosis. Ann Intern Med 1971;74: 875–881.
98. Nakashima M, Maeda K, Sekiya A, et al: Effect of hypothyroid status on myocardial responses to sympathomimetic drugs. Jpn J Pharmacol 1971;21: 819–825.
99. Rosenqvist U, Boreus LO: Enhancement of the alpha-adrenergic response in aorta from hypothyroid rabbits. Life Sci 1972;2: 595–604.
100. Rosenqvist U: Noradrenaline-induced lipolysis in subcutaneous adipose tissue from hypothyroid subjects. Acta Med Scand 1972;192: 361–369.
101. Grill V, Rosenqvist U: Inhibition of the noradrenaline induced adenyl cyclase stimulation by augmented and adrenergic response in subcutaneous adipose tissue from hypothyroid subjects. Acta Med Scand 1973;194: 129–132.
102. Harlan WR, Laslo I, Bogdonoff MD, et al: Alterations in free fatty acid metabolism in endocrine disorders: Part I. Effect of thyroid hormone. J Clin Endocrinol Metab 1963;23: 33–40.
103. Guttler RB, Shaw JW, Otis CL, et al: Epinephrine-induced alterations in urinary cyclic AMP in hyper- and hypothyroidism. J Clin Endocrinol Metab 1975;41: 707–711.
104. Palacios JM, Kuhar MJ: β-Adrenergic receptor localization by light microscopic autoradiography. Science 1980;208: 1378–1380.
105. Menneman KP, Dibner MD, Wolfe BB, et al: β1 and β2 adrenergic receptors in rat cerebral cortex are independently regulated. Science 1979;25: 866–868.
106. Frazer A, Pandy G, Mendels L, et al: The effect of triiodothyronine in combination with imipramine on C-AMP production in slices of rat cerebral cortex. Neuropharmacology 1974;13: 1131–1140.
107. Bernard C: An Introduction to the Study of Experimental Medicine, Greene HC (trans). New York, Macmillan Publishing Co Inc, 1927.
108. Pederson AM, Barry DJ, Babigian HM: Epidemiological considerations of psychotic depression. Arch Gen Psychiatry 1972;27: 193–197.
109. Ziegler LH, Levine BS: The influence of emotional reactions on basal metabolism. Am J Med Sci 1925;169: 68–76.
110. Reus VI, Gold P, Post R: Lithium induced thyrotoxicosis. Am J Psychiatry 1979;136: 724–725.
111. Waal H: Propranolol induced depression. Br Med J 1967;2: 50–52.
112. Simpson FO: Hypertension and depression and their treatment. Aust NZ J Psychiatry 1973;7: 133–137.
113. Rackensperger W, Fritsch W, Schwarz D, et al: The effect of the beta adrenergic blocking agent propranolol in mania. Arch Psychiatr Nervenkr 1976;222: 223–243.
114. Atsmon A, Blum I: Propranolol and psychosis: The initial discovery, in Roberts E, Amacher P (eds): Propranolol and Schizophrenia. New York, Alan R Liss Inc, 1978.
115. Simon P, Lecrubier Y, Jouvent R, et al: Experimental and clinical evidence of the antidepressant effect of a beta-adrenergic stimulant. Psychol Med 1978;8: 335–338.
116. Lecrubier Y, Puech AJ, Jouvent R, et al: A β-adrenergic stimulant (salbutamol) versus clomipramine in depression: A controlled study. Br J Psychiatry 1980;136: 354–358.
117. Hamburg DA, Lunde DT: Relation of behavioral genetic and neuroendocrine factors in thyroid function, in Spuhler JN (ed): Genetic Diversity and Human Behavior. Chicago, Aldine Publishing Co, 1967.
118. Whybrow PC, Ferrell R: Thyroid state and human behavior: Contributions from a clinical perspective, in Prange AJ (ed): The Thyroid Axis, Drugs, and Behavior. New York, Raven Press, 1974.